Teva Pharmaceutical announced the launch of Capecitabine Tablets, the generic equivalent to Genentech's Xeloda.
A novel blood-based biomarker test has been shown to predict with over 90% accuracy the likelihood of a healthy individual developing mild cognitive impairment or Alzheimer's disease within three years.
The FDA has warned consumers that the sexual enhancement supplement Weekend Warrior contains an undisclosed ingredient and should not be purchased or used.
The American Academy of Pain Medicine (AAPM) has issued a position paper warning state and private insurers regarding methadone as a drug of first choice for chronic pain.
The FDA has concluded that compared to the use of imipenem and cilastatin for injection, Doribax carries an increased risk of death and lower clinical cure rates.